BioNTech Completes Acquisition of Kite’s Neoantigen TCR Cell Therapy R&D Platform and ...
August 4, 2021, 2:03 pm
BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Kite, a Gilead Company (Nasdaq: GILD, “Kite”) today announced the closing of the acquisition of the solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility’s assets and leases in Gaithersburg,
